RLS GLOBAL AB (PUBL) RAISES A SHORT-TERM LOAN OF MSEK 5.0
RLS Global AB (publ) (“RLS”) or the “Company”) has today, 24 August 2023, raised a short-term loan of MSEK 5.0 from a number of external investors.
The loan matures on 31 December 2023 and has a fixed interest rate of 8 percent. In the event that the Company carries out a capital raise before 31 December 2023, the loan shall be repaid in connection with completion of such capital raise.
RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the below contact person, 24-08-2023 18:30 CET.
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.
FOR MORE INFORMATION, PLEASE CONTACT:
Roland Frösing, acting CEO, RLS Global
E-mail: roland.frosing@rlsglobal.se
Phone: +46 723 20 61 00
ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company’s platform technology and its unique features will help many patients around the world. Read more at rls.global